NOK 1.9
(-5.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 33.75 Million NOK | -1.52% |
2022 | 34.27 Million NOK | 59.29% |
2021 | 21.51 Million NOK | 4.97% |
2020 | 20.49 Million NOK | -31.77% |
2019 | 30.03 Million NOK | 20.89% |
2018 | 24.84 Million NOK | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 8.6 Million NOK | 0.0% |
2024 Q1 | 8.6 Million NOK | 17.23% |
2023 Q4 | 7.33 Million NOK | 0.0% |
2023 FY | 33.75 Million NOK | -1.52% |
2023 Q1 | 7.8 Million NOK | -22.26% |
2023 Q3 | 7.33 Million NOK | 0.0% |
2023 Q2 | - NOK | -100.0% |
2022 Q4 | 10.03 Million NOK | 0.0% |
2022 FY | 34.27 Million NOK | 59.29% |
2021 FY | 21.51 Million NOK | 4.97% |
2020 FY | 20.49 Million NOK | -31.77% |
2019 FY | 30.03 Million NOK | 20.89% |
2018 FY | 24.84 Million NOK | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Aqua Bio Technology ASA | 1.55 Million NOK | -2063.875% |
ArcticZymes Technologies ASA | 118.93 Million NOK | 71.624% |
BerGenBio ASA | 354 Thousand NOK | -9433.903% |
Hofseth BioCare ASA | 194.87 Million NOK | 82.681% |
PCI Biotech Holding ASA | 2.99 Million NOK | -1028.763% |
Thor Medical ASA | - NOK | -Infinity% |
Ultimovacs ASA | - NOK | -Infinity% |